◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › H › HCM

HUTCHMED DRC (HCM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-12

HUTCHMED DRC (HCM) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Hong Kong, Hong Kong with about 1,790 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, HCM reported $550M in revenue and $458M in net income.

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.

Interactive charts & full statements → Open the HCM valuation workbench →

HCM Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$549M	$550M	$630M	$838M	$426M	$356M	$228M	$205M	$214M	$241M	$216M	$178M	$87M	$46M	$22M	$165M	$135M	$111M	$87M	$65M	$50M
Gross Profit	$1M	$213M	$283M	$454M	$115M	$327M	$40M	$45M	$70M	$65M	$60M	$67M	$28M	$24M	$10M	$91M	$80M	$66M	$51M	$37M	$29M
Gross Margin %	0.2%	38.7%	44.8%	54.1%	27.0%	91.9%	17.3%	21.8%	32.8%	27.1%	27.7%	37.8%	32.6%	51.7%	43.0%	55.2%	59.4%	59.8%	58.5%	57.5%	57.7%
Operating Income (EBIT)	($35M)	($55M)	($44M)	$18M	($719M)	($357M)	($199M)	($153M)	($93M)	($53M)	($47M)	($10M)	($18M)	($1M)	($17M)	$4M	($2M)	($5M)	($14M)	($10M)	($5M)
Operating Margin %	-6.3%	-10.0%	-6.9%	2.2%	-168.6%	-100.3%	-87.0%	-74.6%	-43.3%	-22.1%	-21.6%	-5.5%	-20.9%	-2.3%	-78.0%	2.5%	-1.6%	-4.2%	-16.4%	-14.9%	-10.7%
Net Income	$18M	$458M	$38M	$101M	($361M)	($195M)	($126M)	($106M)	($75M)	($27M)	$12M	$8M	($33M)	$6M	$4M	$1M	($7M)	($9M)	($18M)	($17M)	($10M)
Net Margin %	3.3%	83.3%	6.0%	12.0%	-84.6%	-54.7%	-55.1%	-51.7%	-34.9%	-11.1%	5.4%	4.5%	-37.6%	12.9%	16.3%	0.4%	-5.1%	-7.9%	-20.4%	-26.4%	-19.1%
EBITDA	($21M)	($41M)	($31M)	$27M	($360M)	($155M)	($193M)	($135M)	($82M)	($50M)	($43M)	($8M)	($17M)	$12M	$14M	$11M	$2M	$0M	($10M)	($6M)	($3M)
Earnings Per Share (EPS)	$0.10	$2.62	$0.22	$0.58	$-2.13	$-1.23	$-4.51	$-0.80	$-0.56	$-0.22	$0.10	$0.07	$-0.31	$0.06	$0.03	$0.01	$-0.07	$-0.09	$-0.17	$-0.17	$-0.11
Shares Outstanding (M)	175M	175M	175M	174M	169M	159M	28M	133M	133M	123M	120M	109M	106M	106M	105M	105M	103M	102M	102M	102M	91M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HCM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$139M	$139M	$135M	$135M	$139M	$139M	$162M	$162M
Gross Profit	$24M	$24M	($23M)	($23M)	$55M	$55M	($28M)	($28M)
Gross Margin %	17.0%	17.0%	-17.1%	-17.1%	39.6%	39.6%	-17.4%	-17.4%
Operating Income (EBIT)	$0M	$0M	($18M)	($18M)	($2M)	($2M)	($8M)	($8M)
Operating Margin %	0.3%	0.3%	-13.2%	-13.2%	-1.3%	-1.3%	-5.0%	-5.0%
Net Income	$8M	$8M	$1M	$1M	$227M	$227M	$6M	$6M
Net Margin %	5.7%	5.7%	0.7%	0.7%	163.8%	163.8%	3.7%	3.7%
EBITDA	$4M	$4M	($14M)	($14M)	$1M	$1M	($5M)	($5M)
Earnings Per Share (EPS)	$0.05	$0.05	$0.01	$0.01	$1.30	$1.30	$0.03	$0.03
Shares Outstanding (M)	175M	175M	175M	175M	175M	175M	175M	175M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HCM Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$20M	($65M)	$0M	$219M	($269M)	($204M)	($62M)	($81M)	($33M)	($9M)	($10M)	($9M)	$13M	$5M	$16M	$5M	($20M)	$12M	($14M)	($9M)	($4M)
Capital Expenditures (CapEx)	$11M	$24M	$18M	$33M	$37M	$17M	$20M	$9M	$6M	$5M	$4M	$3M	$4M	$2M	$12M	$6M	$9M	$8M	$3M	$7M	$3M
Free Cash Flow (FCF)	$10M	($89M)	($17M)	$187M	($305M)	($221M)	($82M)	($89M)	($39M)	($14M)	($14M)	($13M)	$10M	$3M	$4M	($1M)	($29M)	$4M	($18M)	($16M)	($6M)
FCF Margin %	1.8%	-16.2%	-2.8%	22.3%	-71.6%	-62.1%	-35.8%	-43.7%	-18.3%	-5.8%	-6.4%	-7.1%	11.0%	5.5%	16.0%	-0.7%	-21.2%	3.7%	-20.3%	-24.3%	-12.4%
Dividends Paid	—	—	—	$123M	$87M	$100M	$0M	$28M	$25M	$56M	$12M	$3M	$1M	—	$1M	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HCM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$6M	$6M	$4M	$4M	($36M)	($36M)	$20M	$20M
Capital Expenditures (CapEx)	$3M	$3M	$2M	$2M	$5M	$5M	$4M	$4M
Free Cash Flow (FCF)	$3M	$3M	$2M	$2M	($41M)	($41M)	$16M	$16M
FCF Margin %	2.4%	2.4%	1.2%	1.2%	-29.6%	-29.6%	10.0%	10.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HCM Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.7B	$1.8B	$1.3B	$1.3B	$1.0B	$1.4B	$724M	$465M	$532M	$598M	$342M	$230M	$211M	$186M	$160M	$195M	$160M	$128M	$118M	$128M	$133M
Cash & Cash Equivalents	$107M	$71M	$154M	$284M	$313M	$378M	$236M	$121M	$86M	$85M	$79M	$32M	$39M	$47M	$31M	$54M	$45M	$42M	$38M	$53M	$10M
Total Liabilities	$461M	$502M	$502M	$536M	$393M	$333M	$205M	$152M	$120M	$113M	$138M	$127M	$113M	$81M	$78M	$117M	$91M	$52M	$34M	$30M	$23M
Total Debt (Short + Long-Term)	$22M	$96M	$86M	$83M	$22M	$32M	$33M	$30M	$27M	$32M	$49M	$54M	$65M	$59M	$11M	$30M	$25M	$8M	$8M	$7M	$7M
Total Shareholders' Equity	$1.3B	$1.2B	$760M	$731M	$610M	$987M	$484M	$288M	$389M	$462M	$184M	$83M	$39M	$89M	$71M	$65M	$60M	$66M	$75M	$90M	$103M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HCM viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

AMLX · Amylyx Pharmaceuticals Inc — $4 billion
INDV · Indivior PLC Ordinary Shares — $4 billion
RGC · Regencell Bioscience Holdings Ltd — $3 billion
SUPN · Supernus Pharmaceuticals Inc — $2 billion
BCRX · BioCryst Pharmaceuticals Inc — $2 billion
TRLV · Trulieve Cannabis Corp. — $2 billion
PBH · Prestige Brand Holdings Inc — $2 billion
BHC · Bausch Health Companies Inc — $2 billion

← HCLTECH All “H” companies HCMA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.